Umecrine Cognition is focused on developing innovative treatments for cognitive disorders, particularly those related to chronic neuroinflammation. Their lead drug candidate, golexanolone, is a GABAA receptor-modulating steroid antagonist designed to address neurological disorders caused by the overactivation of GABA-A receptors due to the neurosteroid allopregnanolone. The company has reported promising results from ongoing clinical trials, including a Phase 1b/2a study that aims to evaluate the safety and efficacy of golexanolone in patients with primary biliary cholangitis (PBC). Additionally, Umecrine Cognition is exploring the potential of golexanolone in treating Parkinson's disease, where preclinical studies have shown its ability to conserve dopamine signaling and mitigate symptoms associated with the disease.

The company’s research highlights the role of neuroinflammation in exacerbating cognitive impairments and fatigue, which are prevalent in conditions like PBC and Parkinson's disease. Golexanolone has demonstrated the capacity to normalize brain signaling and improve cognitive function in patients suffering from hepatic encephalopathy, a condition linked to liver dysfunction. Umecrine Cognition's approach aims to provide a comprehensive treatment strategy that not only addresses motor symptoms but also non-motor symptoms, thereby enhancing the overall quality of life for patients without the adverse effects commonly associated with existing therapies.

Sweden

Umecrine Cognition is a pharmaceutical company that is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's drug candidate, golexanolone, has a unique product profile that addresses important clinical needs and is also the only drug of its class under development. Umecrine Cognition is headquartered in Solna, Sweden and is focused on addressing important unmet medical needs in the field of central nervous system disorders.

Umecrine Cognition

Company Details